Highlights of new guidance statements & interesting publications in 2023
๐งต1/11
From @AASLDtweets new guidance statements
Portal HTN
pubmed.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
ACLF
pubmed.ncbi.nlm.nih.gov
@JuanAbraldes @ggarciatsao @AsraniSumeet
AASLD Practice guidance on Acute-on-chronic liver failure and the management of critically Ill patients with cirrhosis - PubMed
AASLD Practice guidance on Acute-on-chronic liver failure and the management of critically Ill patie...
AASLD Practice Guidance on the use of TIPS, variceal embolization, and retrograde transvenous obliteration in the management of variceal hemorrhage - PubMed
AASLD Practice Guidance on the use of TIPS, variceal embolization, and retrograde transvenous oblite...
AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis - PubMed
AASLD practice guidance on risk stratification and management of portal hypertension and varices in...
From @EASLnews
ACLF
pubmed.ncbi.nlm.nih.gov
Management of intrahepatic CCA
pubmed.ncbi.nlm.nih.gov
Management of liver disease in pregnancy
pubmed.ncbi.nlm.nih.gov
Delta virus
pubmed.ncbi.nlm.nih.gov
#livertwitter
EASL Clinical Practice Guidelines on the management of liver diseases in pregnancy - PubMed
Liver diseases in pregnancy comprise both gestational liver disorders and acute and chronic hepatic...
EASL Clinical Practice Guidelines on hepatitis delta virus - PubMed
Hepatitis D virus (HDV) is a defective virus that requires the hepatitis B virus to complete its lif...
EASL Clinical Practice Guidelines on acute-on-chronic liver failure - PubMed
Acute-on-chronic liver failure (ACLF), which was described relatively recently (2013), is a severe f...
EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma - PubMed
Intrahepatic cholangiocarcinoma (iCCA) develops inside the liver, between bile ductules and the seco...
From @APASLnews
Ascites management
pubmed.ncbi.nlm.nih.gov
From @AmCollegeGastro
New ALF guidelines
pubmed.ncbi.nlm.nih.gov
#livertwitter
Asia-Pacific association for study of liver guidelines on management of ascites in liver disease - PubMed
Asia-Pacific association for study of liver guidelines on management of ascites in liver disease
Acute Liver Failure Guidelines - PubMed
Acute liver failure (ALF) is a rare, acute, potentially reversible condition resulting in severe liv...
From @AGA_Gastro
NIT in MASL
pubmed.ncbi.nlm.nih.gov
Use of vasoactive drugs and albumin in cirrhosis
pubmed.ncbi.nlm.nih.gov
#livertwitter
AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review - PubMed
This expert review was commissioned and approved by the American Gastroenterological Association (AG...
AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review - PubMed
This Expert Review was commissioned and approved by the AGA Institute Clinical Practice Updates Comm...
Highlights in ArLD
How to deal with discordant Peth results
pubmed.ncbi.nlm.nih.gov
Integrated management with AUD
pubmed.ncbi.nlm.nih.gov
Cause-specific mortality in ArLD
pubmed.ncbi.nlm.nih.gov
Practical tips for ArLD management
pubmed.ncbi.nlm.nih.gov
#livertwitter
Cause-specific mortality in patients with alcohol-related liver disease in Denmark: a population-based study - PubMed
TrygFonden and the Novo Nordisk Foundation.
Alcohol-Associated Liver Disease: Integrated Management With Alcohol Use Disorder - PubMed
Alcohol-associated liver disease (ALD) is the most common cause of cirrhosis and liver-related morta...
"But I didn't drink!": What to do with discordant phosphatidylethanol results - PubMed
Liver transplantation (LT) teams must be adept at detecting, evaluating, and treating patients' alco...
Practical Considerations to Optimize Care for Patients With Alcohol-Associated Liver Disease in General Gastroenterology Practice - PubMed
Practical Considerations to Optimize Care for Patients With Alcohol-Associated Liver Disease in Gene...
Results of IMPORTAL
pubmed.ncbi.nlm.nih.gov
Results of IMbrave050
pubmed.ncbi.nlm.nih.gov
Non invasive assessment of decomp
pubmed.ncbi.nlm.nih.gov
@MajaThiele
Fatty liver's new name
pubmed.ncbi.nlm.nih.gov
#livertwitter
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial - PubMed
F Hoffmann-La Roche/Genentech.
A multisociety Delphi consensus statement on new fatty liver disease nomenclature - PubMed
The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder te...
Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis - PubMed
Anticoagulation is effective in promoting recanalization of portal vein thrombosis in patients with...
Non-invasive assessment of hepatic decompensation - PubMed
Non-invasive tests (NITs) are used in all aspects of liver disease management. Their most prominent...
In HRS-AKI
Advances in HRS management
@AGA_CGH
pubmed.ncbi.nlm.nih.gov
Practical tips on management of HRS-AKI
@AmCollegeGastro
pubmed.ncbi.nlm.nih.gov
#livertwitter
@AmJGastro
Recent Advances in the Management of Hepatorenal Syndrome: A US Perspective - PubMed
Recent Advances in the Management of Hepatorenal Syndrome: A US Perspective
Practical Management of HRS-AKI in the Era of Terlipressin: What the Gastroenterologist Needs to Know - PubMed
Practical Management of HRS-AKI in the Era of Terlipressin: What the Gastroenterologist Needs to Kno...
Reviews
AKI in cirrhosis @NEJM
pubmed.ncbi.nlm.nih.gov
Hemochromatosis @TheLancet
pubmed.ncbi.nlm.nih.gov
Hemostasis in cirrhosis
pubmed.ncbi.nlm.nih.gov
Management of cirrhosis @ebtapper
pubmed.ncbi.nlm.nih.gov
Liver transplant
pubmed.ncbi.nlm.nih.gov
#livertwitter
Diagnosis and Management of Cirrhosis and Its Complications: A Review - PubMed
Approximately 2.2 million US adults have cirrhosis. Many symptoms, such as muscle cramps, poor-quali...
Haemochromatosis - PubMed
Haemochromatosis is one of the most common genetic diseases affecting patients of northern European...
Haemostasis in cirrhosis: Understanding destabilising factors during acute decompensation - PubMed
Hospitalised patients with decompensated cirrhosis are in a rebalanced haemostatic state due to a pa...
Liver Transplantation - PubMed
Liver Transplantation
Acute Kidney Injury in Patients with Cirrhosis - PubMed
Acute Kidney Injury in Patients with Cirrhosis
Is there a final verdict on albumin?
Position statement
pubmed.ncbi.nlm.nih.gov
Controversies of albumin use in cirrhosis
pubmed.ncbi.nlm.nih.gov
#livertwitter
Controversies regarding albumin therapy in cirrhosis - PubMed
Albumin is the most abundant protein in the human body and is synthetized exclusively by the liver....
Use of albumin infusion for cirrhosis-related complications: An international position statement - PubMed
Thirty-three investigators from 19 countries proposed 12 position statements on the use of human alb...
Carvedilol is the new NSBB of choice
pubmed.ncbi.nlm.nih.gov
National cohort study of NSBB in decomp/mortality
pubmed.ncbi.nlm.nih.gov
@serperm
How good are NSBBs?
pubmed.ncbi.nlm.nih.gov
TIPS improves survival
pubmed.ncbi.nlm.nih.gov
#livertwitter
Quantifying the benefit of nonselective beta-blockers in the prevention of hepatic decompensation: A Bayesian reanalysis of the PREDESCI trial - PubMed
Beta-blocker treatment is associated with a high probability of clinical benefit. This likely transl...
TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis - PubMed
A further decompensation (new or worsening ascites, variceal bleeding or rebleeding, hepatic encepha...
Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: A national cohort study - PubMed
There is an ongoing need to noninvasively identify patients who may benefit from NSBBs for the preve...
Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension - PubMed
Portal hypertension (PH) is the most common complication ofcirrhosis and represents the main driver...
Personalized management of HCC
pubmed.ncbi.nlm.nih.gov
New practice guidance on HCC @AASLDtweets pubmed.ncbi.nlm.nih.gov
#livertwitter
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept - PubMed
Advances in the surgical and systemic therapeutic landscape of hepatocellular carcinoma have increas...
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma - PubMed
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
@jturnesv @ebtapper @LiverFellow @drkeithsiau @joostphdrenth @JVLazarus @scottisaacsmd @livertox @aelsharkawy75 @stevenbollipo @JesusMBanales @ReibergerThomas @MajaThiele @rabataller #livertwitter
Loading suggestions...